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Objectives: Maraviroc has been shown to be effective in patients harbouring CCR5-tropic HIV-1. While this CCR5
antagonist has initially been used in salvage therapy, its excellent safety profile makes it ideal for antiretroviral
treatment simplification strategies in patients with suppressed plasma viraemia. The aim of this study was to
compare HIV-1 tropism as detected in baseline plasma RNA and peripheral blood mononuclear cell (PBMC) DNA
prior to first-line therapy and to analyse tropism evolution while on successful treatment.
Methods: HIV-1 tropism was determined using triplicate genotypic testing combined with geno2pheno[corecep-
tor] analysis at a 10% false positive rate in 42 patients. Paired pre-treatment plasma RNA and PBMC DNA and two
subsequent PBMC DNA samples (the first obtained after reaching undetectable plasma HIV-1 RNA and the second
after at least 2 years of suppression of plasma viraemia) were evaluated.
Results:Coreceptor tropism was completely concordant in paired pre-treatment RNA and DNA, with 26.2% of HIV-
1 sequences predicted to be non-CCR5-tropic. During follow-up, coreceptor tropism switches were detected in 4
(9.5%) patients without any preferential direction. Although false positive rate discrepancies within triplicates
were common, the rate of discordance of coreceptor tropism assignment among triplicate results in this mostly
CCR5-tropic dataset was only 2.1%, questioning the added value of triplicate testing compared with single testing.
Conclusions: HIV-1 coreceptor tropism changes during virologically successful first-line treatment are infrequent.
HIV-1 DNA analysis may thus support the choice of a CCR5 antagonist in treatment switch strategies; however,
maraviroc treatment outcome data are required to confirm this option.
Keywords: HIV type 1, V3, gp120, genotype interpretation
Introduction
Maraviroc is the only coreceptor antagonist currently licensed for
treatment of HIV-1 infection.1 Determining HIV coreceptor
tropism is a prerequisite before maraviroc treatment because
HIV-1 can use the CCR5 (R5 virus) or CXCR4 (X4 virus) membrane
receptors, or both (DM virus), to enter target cells and maraviroc
is effective only against R5 virus. While HIV-1 coreceptor tropism
can be measured phenotypically by a few highly complex standar-
dized assays, most of the screening of patient candidates for mar-
aviroc treatment in Europe is performed by a genotypic test.2
Genotypic tropism testing is based on the high correlation
between specific sequence motifs in the HIV-1 gp120 hypervari-
able region 3 (V3) and coreceptor usage.
Although maraviroc use in first-line treatment regimens is
acceptable under special circumstances,3 virtually all patients
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undergoing maraviroc-based therapy have previously failed anti-
retroviral therapy (ART). An interesting option gaining attention is
switching to maraviroc-containing regimens in patients with sup-
pressed viremia.4 The main reason for this strategy is the excellent
safety profile of maraviroc, which can decrease treatment toxicity
and thuspossibly improveadherence.5 However, coreceptor tropism
in these patients cannot be determined using plasma HIV-1 RNA,
which has been used in clinical trials. Possible alternatives include
testing peripheral blood mononuclear cell (PBMC) HIV-1 DNA or
the last available plasma HIV-1 RNA sample with detectable vir-
aemia.Few studies6 –8have so faraddressed this issue, and only par-
tially, as they analysed small or unselected patient populations and
failed to use triplicate testing, which is now recommended by
current European genotypic coreceptor tropism testing guidelines.2
In this study we compared baseline coreceptor tropism, as
detected by triplicate HIV-1 plasma RNA and PBMC DNA sequen-
cing before successful first-line therapy, and evaluated the evolu-
tion of tropism in HIV-1 PBMC DNA while on suppressive therapy
in a total of 42 patients. In addition, the use of triplicate analysis
allowed us to estimate the difference in sensitivity and specificity
of detection of X4/DM virus by single compared with triplicate
analysis.
Methods
Plasma and PBMC samples were obtained from the Italian Cohort of Anti-
retroviral Naive Patients (ICONA) biobank upon patients’ informed
consent. Selection criteria included achieving undetectable viraemia
(defined as HIV-1 RNA,50 copies/mL) within a maximum of 32 weeks of
first-line treatment and remaining on continued suppressive therapy.
Paired plasma and PBMC samples were collected within 4 weeks of the
start of ART (pre-ART RNA and pre-ART DNA). Two follow-up DNA samples
had to be available, the first after reaching undetectable plasma HIV-1
RNA (T1 DNA) and the second after at least 2 years of continued virological
suppression (T2 DNA).
Plasma RNAwas extracted using the QIAamp Viral RNA Mini Kit (Qiagen,
Hilden, Germany) following virus enrichment through centrifugation of
1.8 mL of plasma. PBMC DNA was extracted by using the High Pure Viral
Nucleic Acid Kit (Roche, Branchburg, NJ, USA) as specified by the manufac-
turer. Triplicate RT–PCR was performed by three separate RT reactions
driven by random hexamers, followed by nested PCR with outer primers
P150 (coordinates 6945–6971 in the HXB2 genome) and P151 (7661–
7689) and inner primers P537 (6955–6976) and P538 (7353–7373). The
RNA extract input volume for each RT–PCR corresponded to 0.6 mL of
plasma. The same HIV-1 DNA region was subjected to triplicate amplifica-
tion from PBMC DNA, representing 50000–100000 cells. Sequencing was
performed with BigDye 3.1 chemistry using an ABI 3130xl apparatus. Elec-
tropherograms were manually edited by one operator using the DNAstar
Seqman Pro 7.1.0 software module and sample coding was blinded until
completion of analysis of all samples.
Sequences were interpreted using the geno2pheno[coreceptor] algo-
rithm (http://coreceptor.bioinf.mpi-inf.mpg.de/index.php). Primaryanalysis
was done considering virus as R5 when all of the three replicate sequences
had a false positive rate (FPR)≥10% and as X4/DM when at least one repli-
cate sequence had an FPR ,10%, as recommended in current genotypic
tropism testing guidelines.2 Sensitivity, specificity, positive predictive
value and negative predictive value were referred to detection of X4/DM
virus. In addition, because the need for triplicate analysis in clinical practice
is not widely accepted,9 concordance between single and triplicate testing
was analysed considering 10% and 20% FPR for single testing and 10% and
5.75% for triplicate testing, based on guidelines and on clinical validation of
triplicate genotypic tropism testing using clinical trial data.10,11 To
determine the rate of agreement between single and triplicate analysis,
the single FPR value was generated bycomputer-assisted random selection
of one of the three triplicates and compared with the lowest FPR value
obtained for the corresponding triplicate analysis. The process was
repeated 1000 times and the mean+SD was calculated.
To verify inter- and intra-patient data consistency, all the sequences
obtained underwent phylogenetic analysis by the neighbour-joining
method using the PHYLIP software package version 3.69 (http://evolution.
genetics.washington.edu/phylip.html).
Results
Baseline characteristics of patients
Table 1 shows the characteristics of the 42 patients included in the
study. Due to low sample quality or labelling inconsistencies, two
pre-ART DNA samples and three follow-up samples (one T1 DNA
and two T2 DNA) obtained from five different patients could not
be analysed. Thus, 163 samples (42 plasma and 121 PBMC) from
42 patients were analysed. A minority of sequences [5 of 363
(1.4%) from three DNA samples, and 2 of 126 (1.6%) from two
RNA samples] could not be read due to extensive overlap of mul-
tiple quasispecies of different lengths and were discarded from
the analysis.
The median (range) time between pre-ART and T1 DNA and
between T1 DNA and T2 DNA sampling was 57 (50–94) and 120
(80–238) weeks, respectively. Using the reference 10% FPR with
triplicate analysis, 11 of the 42 (26.2%) pre-ART RNA sequences
were labelled as X4/DM. There was complete concordance
between pre-ART RNA and pre-ART DNA tropism in all the 40 avail-
able paired samples. Pre-ART X4/DM tropism was significantly asso-
ciated with lower concomitant CD4 cell counts [median (range)
190 (73–384) versus 371 (294–583) cells/mm3, P,0.001] but
not with concomitant viraemia levels [4.32 (4.09–4.91) versus
4.71 (4.39–5.08) log10 copies/mL, P¼0.155].
Table 1. Characteristics of the patients included in the study, at the time
of ART initiation
Patients, n 42
Age (years), median (IQR) 38 (33–43)
Gender, % male 78.6
Heterosexual route of infection, % 48.0
Time from HIV diagnosis (weeks), median (range) 52 (2–53)
Baseline CD4 (cells/mm3), median (range) 351 (188–520)
Baseline CD8 (cells/mm3), median (range) 1018 (726–1297)
Baseline viral load (log10 HIV RNA copies/mL),
median (range)
4.68 (4.30–5.01)
CDC stage C, % 7.0
Treatment, n
2 NRTIs+1 NNRTI 28
2 NRTIs+PI 11
other 3a
NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside
reverse transcriptase inhibitor; PI, protease inhibitor.
aTwo with 3 NRTIs and one with 3 NRTIs+1 NNRTI.
Meini et al.
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Coreceptor tropism evolution over time
Figure 1 shows coreceptor tropism evolution over time. Tropism
changes were uncommon and did not followany preferential direc-
tion. There were 2 (4.9%) changes (both R5 to X4/DM) from pre-ART
RNA to T1 DNA and 3 (7.7%) changes from T1 DNA to T2 DNA (one
R5 to X4/DM and two X4/DM to R5). When comparing pre-ART RNA
with T2 DNA, changes occurred in 3 (7.5%) cases (two R5 to X4/DM
and one X4/DM to R5). Overall, 4 of the 42 (9.5%) patients analysed
experienced at least one tropism change during the study. FPR
values obtained for the V3 sequences from these patients are
shown in Table 2 (FPR values for all the samples included in the
study are shown in Table S1, available as Supplementary data at
JAC Online). Of note, there was only one patient (patient 2) har-
bouring R5 virus at baseline and permanently switching to X4/DM
during virological suppression. Phylogenetic analysis showed that
for three patients the R5 and X4/DM viruses clustered together
with minor divergence, while the X4/DM virus found in patient 7
only in T1 DNA was a unique population distinct from the R5 virus
detected in pre-ART RNA, pre-ART DNA and T2 DNA (Figure 2).
Due to the low rate of coreceptor tropism changes, it was not pos-
sible to detect any association between patients’ characteristics
and tropism changes over time.
Triplicate versus single sequencing analysis
FPR values were often not identical among triplicates. Of the 158
samples with triplicate results available, 114 (72.2%) were la-
belled as R5 and 44 (27.8%) were labelled as X4/DM based on
the 10% FPR threshold. Two or three different FPR scores were
generated in 43 (27.2%) and 21 (13.3%) triplicate analyses,
respectively. However, only 6 (3.8%) samples, derived from five
patients, showed triplicate FPR values both higher and lower
than the 10% threshold and thus might have generated a false-
negative R5 prediction when analysed in a single test (Table 3).
This discordance rate between single analysis and the reference
triplicate analysis at 10% FPR is a conservative estimate based
on the unlikely worst-case scenario that the single result would
be R5 in all six cases. Indeed, when comparing a 1000-fold
random selection of single results with the corresponding triplicate
result, the mean+SD discordance rate obtained was 2.1+0.7%.
Phylogenetic analysis revealed expected clustering for all of the
sequences obtained from four of the five patients showing dis-
cordant triplicate results (Figure S1, available as Supplementary
data at JAC Online). For patient 19, the three sequences obtained
from pre-ART DNA formed a separate node that did not cluster
with any other sequence in the whole dataset, likely reflecting
Patient 2
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RNA
Patient 7
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Patient 25
DNA at viraemia
DNA at median 3
years (range 2.1–
6.0) of continued
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suppression
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2
11
0
28
1
2
1
28
9
R5 to R5 R5 to X4/DMX4/DM to X4/DM X4/DM to R5
Figure 1. Evolution of HIV-1 coreceptor tropism over time in the studied patients. Boxed patient codes refer to the cases where a coreceptor tropism
change occurred as detailed in Table 2.
Table 2. FPR values obtained from triplicate testing of the sample series of the four patients with changes of virus coreceptor tropism over time
Patient ID
Triplicate pre-ART DNA FPR
values
Triplicate pre-ART RNA FPR
values Triplicate T1 DNA FPR values Triplicate T2 DNA FPR values
2 18.5 20.9 24.7 14.7 14.7 26.2 1.7 1.7 1.7 0.7 0.7 0.7
7 26.2 26.2 26.2 26.2 26.2 28.9 0.1 0.1 0.1 32.0 21.4 21.4
25 7.4 9.0 6.8 16.6 6.8 10.8 10.8 10.8 8.9 16.6 15.0 24.9
34 28.7 28.7 28.7 18.2 41.4 41.4 33.5 35.3 35.3 35.3 18.2 4.0
HIV-1 coreceptor tropism evolution during successful HAART
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the existence of a distinct viral population in pre-treatment
PBMC DNA.
Sensitivity, specificity, positive predictive value and negative
predictive value for single versus triplicate analysis at different
FPR thresholds are shown in Table 4. FPR for single analysis was
evaluated at 20% and 10%. FPR for triplicate analysis was evalu-
ated at 10% and 5.75%. Both with the 10% triplicate FPR and the
5.75% triplicate FPR taken as a reference, the increase in sensitivity
when switching from 10% single FPR to 20% single FPR was counter-
balanced by a much larger decrease in specificityand loss in positive
predictive value. Notably, the single test using a 10% FPR threshold
showed sensitivities always .90% and negative predictive values
.96.8% both in RNA and DNA samples, taking detection of X4/DM
using the triplicate testing at 10% FPR as reference (the standard
currently recommended by guidelines). Specificities and negative
predicted values were even higher (96.5% and 98.9%, respectively),
using the triplicate test with 5.75% FPR as reference (the clinically
validated standard).
Discussion
Whiletheappropriatenessofgenotypiccoreceptortropismscreening
for candidate patients for maraviroc treatment has been established
based on the analysis of HIV-1 RNA,10,11 the attractive potential
of maraviroc for treatment simplification requires the analysis of
HIV-1 DNA in patients with suppressed plasma HIV-1 RNA. This
and two previous studies6,8 have addressed the correlation be-
tween genotype-based tropism in HIV-1 DNA following viraemia
suppression and in HIV-1 RNA before viraemia suppression.
Concordance between contemporary HIV-1 RNA and DNA
tropism results obtained in treatment-naive individuals has been
evaluated only in our study and the study conducted by Secle´n
et al.,6 based on comparable numbers of cases. While we found
complete concordance between paired RNA and DNA samples,
Secle´n et al.6 reported an 18.4% discordance rate. Other studies
comparing DNA and RNA genotypic coreceptor tropism in unse-
lected patient populations have reported concordance rates
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Figure2. Phylogenetic tree showing the relationshipsamong the sequences obtainedfrom the four patients showing coreceptor tropism switch during the
study. The taxon labels indicate information in the following order: patient code, sample type (blRNA, pre-ART plasma RNA; blDNA, pre-ART PBMC DNA;
fuDNA1, first follow-up PBMC DNA; fuDNA2, second follow-up PBMC DNA), replicate (a/b/c, required to distinguish sequences by the phylogenetic
tree-building software), geno2pheno[coreceptor] FPR.
Table 3. FPR values obtained from triplicate testing of individual samples
generating both R5 and X4/DM prediction at the 10% FPR cut-off
Patient ID Sample type Sequence 1 Sequence 2 Sequence 3
12 T2 DNA 28.7 1.7 1.7
19 pre-ART DNA 9.0 21.0 21.0
25 pre-ART RNA 16.6 6.8 10.8
25 T1 DNA 10.8 10.8 8.9
34 T2 DNA 35.3 18.2 4.0
37 pre-ART RNA 15.6 9.3 9.3
Meini et al.
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ranging from 82% to 95%.12 – 16 While the small sample size may
have limited the rate of disagreement between DNA- and RNA-
based tropism, the increased concordance in our study can also
be explained by the use of triplicate versus single testing, resulting
in higher probability of detection of X4/DM virus in samples with
both R5 and X4/DM populations. Also, testing patients before first-
line therapy may have selected cases with a shorter duration of HIV
infection compared with other studies, limiting the time of diver-
gent evolution of coreceptor tropism in the plasma and PBMC
compartments.
Tropism switch during follow-up of patients under continuous
suppressive treatment appears to be relatively modest. Despite
variability in the study design and a limited patient sample size,
our results are comparable to those reported by Secle´n et al.6
and Soulie et al.,8 suggesting an average 10% expected rate of
genotypic tropism switch from the last measurement in plasma
RNA before treatment and the follow-up test on PBMC DNA after
at least 1 year of successful treatment. Different from previous
reports analysing tropism only at baseline and one follow-up time-
point,6,8our study considered two follow-up DNA samples and thus
was more powered to detect tropism switch over time. A similar
rate of evolution has also been reported comparing pre-therapy
and post-therapy plasma RNA coreceptor tropism using the
Trofile assay in patients interrupting suppressive therapy.17
Importantly, none of these studies documented any preferential
direction of tropism switch, resulting in around 5% R5 to X4/DM
changes. A low level of HIV-1 replication is the likely explanation
for the limited evolution of HIV-1 coreceptor tropism during sup-
pressive therapy. However, the few cases of switch confirm that
HIV-1 replication cannot be assumed to be completely suppressed
in the context of undetectable viral load as measured by standard
assays.
Overall, these data may support the use of PBMC DNA for geno-
typic coreceptor tropism determination in patients with sup-
pressed viraemia who are candidates for maraviroc treatment,
as suggested by preliminary evidence in patients achieving viral
load suppression after multiple treatment lines.18 However, our
case file included only patients on successful first-line therapy,
who may not be representative of the more likely use of maraviroc
as simplification strategy in more experienced patients. In add-
ition, it is important to note that our patients were not subsequent-
ly treated with maraviroc, so it was not possible to verify the
predictive power of genotypic coreceptor tropism testing with
PBMC DNA. A recent paper by Swenson et al.19 suggested that
PBMC DNA tropism may be slightly less predictive of virological
outcome compared with plasma RNA tropism, although in the dif-
ferent context of viraemic patients starting maraviroc-including
salvage therapy. Thus, more extensive clinical validation is still
required to confirm that HIV-1 DNA coreceptor tropism can reliably
guide the choice of maraviroc-containing simplification regimens.
In addition, parallel testing with the reference phenotypic assay
(the enhanced-sensitivity Trofile assay) is recommended when
any genotypic assay is used in a clinical context.
Triplicate analysis revealed a relativelysmall gain in sensitivityof
X4/DM virus detection compared with single-test analysis. In this
dataset, the percentage of samples yielding FPR values both
below and above the 10% threshold by triplicate testing was only
3.8% using a conservative estimate and2% using random selec-
tion of single-test results. Previous studies have documented
similar discordance rates with duplicate20 or triplicate21 testing
versus single testing. It must be noted that the small sample size
and high prevalence of R5 virus variants may have contributed to
a low discordance rate. On the other hand, in R5-prevalent data-
sets such low discordance rates actually translate into a compara-
tively higher increase in the sensitivity of detection of X4/DM virus.
For example, the 3.8% single versus triplicate discordance rate
in our study results in reclassification from R5 to X4/DM tropism
in six cases, corresponding to a 15.8% increase in detection of
X4/DM virus when triplicate testing is used (from 38/158 to
44/158). This estimate is in agreement with previous studies.20,21
The choice to increase sensitivity by replicate testing or by using
a higher FPR threshold clearly comes at the expense of lower
Table 4. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the detection of X4/DM virus based on 10% and
20% FPR single testing (10% sFPR and 20% sFPR, respectively) versus the gold standard 10% and 5.75% triplicate testing (10% tFPR and 5.75% tFPR)
Analysis Sensitivity Specificity PPV NPV
10% sFPR versus 10% tFPR (DNA and RNA) 92.28+2.63 NA NA 97.12+0.96
10% sFPR versus 10% tFPR (DNA) 93.09+2.71 NA NA 97.28+1.04
10% sFPR versus 10% tFPR (RNA) 90.06+6.63 NA NA 96.83+2.08
20% sFPR versus 10% tFPR (DNA and RNA) 97.04+1.84 81.88+1.20 67.42+1.52 98.63+0.84
20% sFPR versus 10% tFPR (DNA) 96.03+2.45 80.96+1.26 67.14+1.56 98.07+1.18
20% sFPR versus 10% tFPR (RNA) 100.00+0.00 84.39+2.73 68.33+3.86 100.00+0.00
10% sFPR versus 5.75% tFPR (DNA and RNA) 97.15+1.93 94.60+0.74 83.71+1.88 99.15+0.57
10% sFPR versus 5.75% tFPR (DNA) 96.54+2.40 94.83+0.73 85.34+1.78 98.88+0.77
10% sFPR versus 5.75% tFPR (RNA) 100.00+0.00 93.96+2.03 78.27+5.88 100.00+0.00
20% sFPR versus 5.75% tFPR (DNA and RNA) 98.07+1.89 76.39+1.17 54.19+1.33 99.29+0.69
20% sFPR versus 5.75% tFPR (DNA) 97.60+2.44 76.34+1.26 56.23+1.47 99.04+0.97
20% sFPR versus 5.75% tFPR (RNA) 100.00+0.00 76.68+2.42 47.77+2.64 100.00+0.00
NA, not applicable (specificity and PPV are 100% by definition).
The analysis was performed on the whole DNA and RNA, and on PBMC DNA and plasma RNA separately. Values are the mean+SD obtained from 1000
random selections of single results.
HIV-1 coreceptor tropism evolution during successful HAART
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specificity, i.e. denying maraviroc treatment to patients who would
benefit from it. Interestingly, a 10% single-test FPR has been shown
to be predictive of response to maraviroc in the French GenoTrop-
ism study.22
It must be noted that the sensitivity and specificity values
reported in our study for single testing at different FPR are related
to the triplicate amplification followed by population sequencing
analysis. This approach is recommended by European guidelines2
but is expected to have lower sensitivity than the clinically vali-
dated phenotypic gold standard.23 Indeed, a proper assessment
of the performance of any genotypic tropism assay can only be
obtained when the reference phenotypic results are available.
Overall, the most appropriate and cost-effective laboratory proce-
dures and threshold FPR remain to be established, particularly in
light of the forthcoming introduction of ultradeep sequencing
protocols that allow more sensitive detection of X4/DM virus com-
pared with population sequencing.23 European guidelines recom-
mend that the geno2pheno tropism testing report includes the
method used (e.g. triplicate analysis), the FPR values obtained
and clear advice as to whether the tropism result supports the
use of a CCR5 antagonist or not. As with genotypic resistance
testing for the other antiretroviral classes, genotypic tropism
testing results may fall into a ‘grey zone’, where the clinician ultim-
ately has to balance the uncertainty of the efficacy of a CCR5
antagonist in the context of the specific patient status.
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